Loading
PDBj
✖
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9UVU

Cryo-EM structure of bradykinin B2 receptor (B2R)-BRIL/anti BRIL SRP2070 Fab antibody complex with icatibant, focused on receptor

This is a non-PDB format compatible entry.
Summary for 9UVU
Entry DOI10.2210/pdb9uvu/pdb
EMDB information64537
Descriptoricatibant, B2 bradykinin receptor,Soluble cytochrome b562 (2 entities in total)
Functional Keywordsgpcr, b2r, bradykinin, icatibant, membrane protein
Biological sourceHomo sapiens (human)
More
Total number of polymer chains2
Total formula weight56147.40
Authors
Kojima, A.,Kawakami, K.,Kobayashi, K.,Matsui, T.E.,Gu, Y.,Fukuda, M.,Kato, H.E. (deposition date: 2025-05-11, release date: 2026-05-06, Last modification date: 2026-10-28)
Primary citationKojima, A.,Kawakami, K.,Kobayashi, N.,Kobayashi, K.,Matsui, T.E.,Uemoto, K.,Gu, Y.,Narita, T.J.,Kugawa, M.,Fukuda, M.,Kato, H.E.
Universal pipeline for high-resolution GPCR structure determination.
Nat.Struct.Mol.Biol., 33:1393-1405, 2026
Cited by
PubMed Abstract: G protein-coupled receptors (GPCRs) regulate human physiology and are major drug targets. Although cryo-electron microscopy has accelerated GPCR structural biology, inactive-state structures remain difficult because current fusion-based strategies often require extensive experimental screening to identify rigid constructs suitable for high-resolution reconstruction. Here we introduce a universal pipeline that integrates an in silico fusion construct screening program, NOAH (nonexperimental, artificial-intelligence-assisted, high-throughput construct screening for structural analysis), with a de novo designed fusion protein, ARK1 (artificially designed fiducial marker). NOAH enabled structure determination of vasopressin V2 receptor bound to the antagonist tolvaptan or partial agonist OPC51803 and bradykinin B2 receptor bound to the antagonist icatibant, revealing receptor activation and inhibition mechanisms. Coupling NOAH to ARK1 improved the V2 receptor-tolvaptan map and enabled high-resolution structures of lysophosphatidic acid receptor 2 bound to Ki16425 and free fatty acid receptor 2 bound to GLPG0974. NOAH-ARK1 minimizes trial-and-error construct optimization and provides a broadly applicable route for GPCR structural analysis and drug discovery.
PubMed: 42665663
DOI: 10.1038/s41594-026-01869-6
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (3.69 Å)
Structure validation

263157

PDB entries from 2026-11-18

PDB statisticsPDBj update infoContact PDBjnumon